Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

PRAMIPEXOLE FOR SYSTEM SUITABILITY CRS (15 MG)

PRAMIPEXOLE FOR SYSTEM SUITABILITY CRS (15 MG)

191217-81-9

DISCOVER
TIOTROPIUM BROMIDE MONOHYDRATE CRS (15 MG)

TIOTROPIUM BROMIDE MONOHYDRATE CRS (15 MG)

139404-48-1

DISCOVER
Tiotropium for system suitability 10 mg

Tiotropium for system suitability 10 mg

139404-48-1

DISCOVER
GALANTAMINE NATURAL FOR SYSTEM SUITABILITY CRS (10 MG)

GALANTAMINE NATURAL FOR SYSTEM SUITABILITY CRS (10 MG)

04/04/1953

DISCOVER
GALANTAMINE SYNTHETIC FOR SYSTEM SUITABILITY CRS (5 MG)

GALANTAMINE SYNTHETIC FOR SYSTEM SUITABILITY CRS (5 MG)

04/04/1953

DISCOVER
HEPATITIS A VACCINE (INACTIVATED, NON ADSORBED) BRP (1 ML)

HEPATITIS A VACCINE (INACTIVATED, NON ADSORBED) BRP (1 ML)

ND

DISCOVER
CLAZURIL CRS (10 MG)

CLAZURIL CRS (10 MG)

101831-36-1

DISCOVER
RESVERATROL CRS (25 MG)

RESVERATROL CRS (25 MG)

501-36-0

DISCOVER
STRYCHNINE CRS (30 MG)

STRYCHNINE CRS (30 MG)

57-24-9

DISCOVER
BRUCINE CRS (30 MG)

BRUCINE CRS (30 MG)

357-57-3

DISCOVER
CETIRIZINE FOR PEAK IDENTIFICATION CRS (1.01 MG)

CETIRIZINE FOR PEAK IDENTIFICATION CRS (1.01 MG)

83881-52-1

DISCOVER
VARICELLA VACCINE (LIVE) BRP (420 MG)

VARICELLA VACCINE (LIVE) BRP (420 MG)

NA

DISCOVER